title: ACP-103, a 5-HT2A receptor inverse agonist.
abstract: ACADIA Pharmaceuticals is developing ACP-103, lead compound in a series of 5-HT2A inverse agonists, as a potential antipsychotic agent and for the potential treatment of insomnia. Phase II clinical trials in treatment-induced psychosis in Parkinson's disease (PD) patients and in schizophrenic patients are ongoing, as are phase II trials evaluating the effects of the drug on PD symptoms and dyskinesias.
authors.affiliation: Psychiatry Centre of Excellence for Drug Discovery, New Frontiers Science Park, GlaxoSmithKline plc, Harlow, UK. Claire.Roberts@gsk.com
authors.forename: Claire
authors.initials: C
authors.lastname: Roberts
mesh_terms: D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D000075202:Contraindications; D006801:Humans; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D044402:Receptor, Serotonin, 5-HT2A / Q000187:drug effects*; D017366:Serotonin Receptor Agonists / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D013329:Structure-Activity Relationship; D014508:Urea / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity
chemical_list: D010880:Piperidines; D044402:Receptor, Serotonin, 5-HT2A; D017366:Serotonin Receptor Agonists; D014508:Urea; C510793:pimavanserin